1njs

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1njs" size="450" color="white" frame="true" align="right" spinBox="true" caption="1njs, resolution 1.98&Aring;" /> '''human GAR Tfase in ...)
Line 1: Line 1:
-
[[Image:1njs.gif|left|200px]]<br />
+
[[Image:1njs.gif|left|200px]]<br /><applet load="1njs" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1njs" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1njs, resolution 1.98&Aring;" />
caption="1njs, resolution 1.98&Aring;" />
'''human GAR Tfase in complex with hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid'''<br />
'''human GAR Tfase in complex with hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid'''<br />
==Overview==
==Overview==
-
Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target, of anti-neoplastic intervention for almost two decades. Here, we use a, structure-based approach to design a novel folate analogue, 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid, (10-CF(3)CO-DDACTHF, 1), which specifically inhibits recombinant human GAR, Tfase (K(i) = 15 nM), but is inactive (K(i) &gt; 100 microM) against other, folate-dependent enzymes that have been examined. Moreover, compound 1 is, a potent inhibitor of tumor cell proliferation (IC(50) = 16 nM, CCRF-CEM), which represents a 10-fold improvement over Lometrexol, a GAR Tfase, inhibitor that has been in clinical trials. Thus, this folate analogue 1, is among the most potent and selective inhibitors known toward GAR Tfase., Contributing to its efficacious activity, compound 1 is effectively, transported into the cell by the reduced folate carrier and, intracellularly sequestered by polyglutamation. The crystal structure of, human GAR Tfase with folate analogue 1 at 1.98 A resolution represents the, first structure of any GAR Tfase to be determined with a cofactor or, cofactor analogue without the presence of substrate. The folate-binding, loop of residues 141-146, which is highly flexible in both Escherichia, coli and unliganded human GAR Tfase structures, becomes highly ordered, upon binding 1 in the folate-binding site. Computational docking of the, natural cofactor into this and other apo or complexed structures provides, a rational basis for modeling how the natural cofactor, 10-formyltetrahydrofolic acid interacts with GAR Tfase, and suggests that, this folate analogue-bound conformation represents the best template to, date for inhibitor design.
+
Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target of anti-neoplastic intervention for almost two decades. Here, we use a structure-based approach to design a novel folate analogue, 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid (10-CF(3)CO-DDACTHF, 1), which specifically inhibits recombinant human GAR Tfase (K(i) = 15 nM), but is inactive (K(i) &gt; 100 microM) against other folate-dependent enzymes that have been examined. Moreover, compound 1 is a potent inhibitor of tumor cell proliferation (IC(50) = 16 nM, CCRF-CEM), which represents a 10-fold improvement over Lometrexol, a GAR Tfase inhibitor that has been in clinical trials. Thus, this folate analogue 1 is among the most potent and selective inhibitors known toward GAR Tfase. Contributing to its efficacious activity, compound 1 is effectively transported into the cell by the reduced folate carrier and intracellularly sequestered by polyglutamation. The crystal structure of human GAR Tfase with folate analogue 1 at 1.98 A resolution represents the first structure of any GAR Tfase to be determined with a cofactor or cofactor analogue without the presence of substrate. The folate-binding loop of residues 141-146, which is highly flexible in both Escherichia coli and unliganded human GAR Tfase structures, becomes highly ordered upon binding 1 in the folate-binding site. Computational docking of the natural cofactor into this and other apo or complexed structures provides a rational basis for modeling how the natural cofactor 10-formyltetrahydrofolic acid interacts with GAR Tfase, and suggests that this folate analogue-bound conformation represents the best template to date for inhibitor design.
==About this Structure==
==About this Structure==
-
1NJS is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PO4 and KEU as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphoribosylglycinamide_formyltransferase Phosphoribosylglycinamide formyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.1.2.2 2.1.2.2] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1NJS OCA].
+
1NJS is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=PO4:'>PO4</scene> and <scene name='pdbligand=KEU:'>KEU</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphoribosylglycinamide_formyltransferase Phosphoribosylglycinamide formyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.1.2.2 2.1.2.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1NJS OCA].
==Reference==
==Reference==
Line 15: Line 14:
[[Category: Phosphoribosylglycinamide formyltransferase]]
[[Category: Phosphoribosylglycinamide formyltransferase]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Benkovic, S.J.]]
+
[[Category: Benkovic, S J.]]
-
[[Category: Boger, D.L.]]
+
[[Category: Boger, D L.]]
[[Category: Desharnais, J.]]
[[Category: Desharnais, J.]]
-
[[Category: Gooljarsingh, L.T.]]
+
[[Category: Gooljarsingh, L T.]]
-
[[Category: Hedrick, M.P.]]
+
[[Category: Hedrick, M P.]]
[[Category: Li, C.]]
[[Category: Li, C.]]
-
[[Category: Marsilje, T.H.]]
+
[[Category: Marsilje, T H.]]
-
[[Category: Olson, A.J.]]
+
[[Category: Olson, A J.]]
[[Category: Tavassoli, A.]]
[[Category: Tavassoli, A.]]
-
[[Category: Wilson, I.A.]]
+
[[Category: Wilson, I A.]]
[[Category: Zhang, Y.]]
[[Category: Zhang, Y.]]
[[Category: KEU]]
[[Category: KEU]]
Line 30: Line 29:
[[Category: protein-cofactor analogue complex]]
[[Category: protein-cofactor analogue complex]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 18:21:58 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:06:51 2008''

Revision as of 12:06, 21 February 2008


1njs, resolution 1.98Å

Drag the structure with the mouse to rotate

human GAR Tfase in complex with hydrolyzed form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid

Overview

Glycinamide ribonucleotide transformylase (GAR Tfase) has been the target of anti-neoplastic intervention for almost two decades. Here, we use a structure-based approach to design a novel folate analogue, 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid (10-CF(3)CO-DDACTHF, 1), which specifically inhibits recombinant human GAR Tfase (K(i) = 15 nM), but is inactive (K(i) > 100 microM) against other folate-dependent enzymes that have been examined. Moreover, compound 1 is a potent inhibitor of tumor cell proliferation (IC(50) = 16 nM, CCRF-CEM), which represents a 10-fold improvement over Lometrexol, a GAR Tfase inhibitor that has been in clinical trials. Thus, this folate analogue 1 is among the most potent and selective inhibitors known toward GAR Tfase. Contributing to its efficacious activity, compound 1 is effectively transported into the cell by the reduced folate carrier and intracellularly sequestered by polyglutamation. The crystal structure of human GAR Tfase with folate analogue 1 at 1.98 A resolution represents the first structure of any GAR Tfase to be determined with a cofactor or cofactor analogue without the presence of substrate. The folate-binding loop of residues 141-146, which is highly flexible in both Escherichia coli and unliganded human GAR Tfase structures, becomes highly ordered upon binding 1 in the folate-binding site. Computational docking of the natural cofactor into this and other apo or complexed structures provides a rational basis for modeling how the natural cofactor 10-formyltetrahydrofolic acid interacts with GAR Tfase, and suggests that this folate analogue-bound conformation represents the best template to date for inhibitor design.

About this Structure

1NJS is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Phosphoribosylglycinamide formyltransferase, with EC number 2.1.2.2 Full crystallographic information is available from OCA.

Reference

Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid., Zhang Y, Desharnais J, Marsilje TH, Li C, Hedrick MP, Gooljarsingh LT, Tavassoli A, Benkovic SJ, Olson AJ, Boger DL, Wilson IA, Biochemistry. 2003 May 27;42(20):6043-56. PMID:12755606

Page seeded by OCA on Thu Feb 21 14:06:51 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools